Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

47.08 +0.92 (+1.98%)
Streaming Delayed Price Updated: 2:35 PM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
3 Unprofitable Stocks We Find Risky
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
News headline image
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 14.4% over... 
Via StockStory
Topics Stocks
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
A Preview Of Supernus Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Supernus Pharmaceuticals (NASDAQ:SUPN) and... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals. 
Via The Motley Fool
News headline image
3 Russell 2000 Stocks Walking a Fine Line
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
News headline image
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
5 Must-Read Analyst Questions From Supernus Pharmaceuticals’s Q3 Earnings Call
Supernus Pharmaceuticals reported Q3 results that were above Wall Street’s revenue and profit expectations, but the market reacted negatively, reflecting concerns over execution challenges and forward... 
Via StockStory
Topics Earnings
News headline image
Why Supernus Pharmaceuticals (SUPN) Shares Are Trading Lower Today
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 16.8% in the morning session after the company's third-quarter 2025 earnings report, as a weak full-year forecast... 
Via StockStory
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
SUPN Q3 Deep Dive: Growth Drivers Offset By Supply Constraints and Integration Costs
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 CY2025, with sales up 9.3% year on year to $192.1 million. On the other hand, the... 
Via StockStory
Topics Supply Chain
News headline image
Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Strong Q3
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.3% year on year to $192.1 million. On the... 
Via StockStory
News headline image
Supernus Announces Third Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Supernus Pharmaceuticals (SUPN) Reports Q3: Everything You Need To Know Ahead Of Earnings
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings this Tuesday after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Cash-Producing Stocks That Fall Short
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Emerges as a Top Affordable Growth Candidate ↗
Supernus Pharmaceuticals (SUPN) offers affordable growth with strong EPS, solid financials, and a low P/E ratio, making it a compelling investment opportunity. 
Via Chartmill
News headline image
Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings) ↗
 
Via Benzinga
News headline image
3 Small-Cap Stocks We’re Skeptical Of
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Stocks Under $50 We Steer Clear Of
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
News headline image
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Presents a Compelling Mix of Growth and Technical Momentum ↗
Supernus Pharmaceuticals (SUPN) is a strong growth stock with a debt-free balance sheet and a positive technical breakout pattern. Explore its potential. 
Via Chartmill
News headline image
Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Supernus Pharmaceuticals (NASDAQ:SUPN)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Supernus Pharmaceuticals (SUPN) Stock Is Up, What You Need To Know
Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 4.6% in the morning session after Piper Sandler upgraded the company's stock from a "Neutral" to an "Overweight"... 
Via StockStory
Topics Artificial Intelligence
News headline image
Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.